What one large joint-care study found

Track one daily change

Choose either walking distance, stair use, or nights awakened by soreness. Record only that choice for a normal week before care.

After care, record the same activity at the same part of your day. This keeps one unusually good afternoon from looking like lasting relief.

Bring those notes to the next exam. Your provider can then compare the same task before and after care.

Ask when to check again

Relief can appear at different times, so ask when a fair check occurs. Find out when your usual activity may safely begin again.

One better afternoon doesn't show whether relief will last. Keep brief notes about better days and setbacks until your next visit.

Ask what the study measured

When a clinic cites research, ask whether it measured soreness, movement, or an X-ray. Easier walking matters even when the X-ray still shows worn cartilage.

Less soreness doesn't prove that worn tissue grew back. A change seen on an X-ray also doesn't prove that daily movement improved.

Check the limits before choosing

Ask how many people joined, which joint was studied, and what care was compared. Also ask whether the clinic uses the same material used in that study.

If those details aren't given, the study may not answer your question. Once a doctor, nurse practitioner, or physician assistant has checked you, QC Kinetix may offer regenerative care: a blood- or marrow-based shot without surgery.

Sources

1. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

3. A phase 3 placebo-controlled trial of 146 patients using allogeneic bone marrow-derived MSCs (25 million cells) plus hyaluronic acid reported significant WOMAC improvement versus placebo at 6 and 12 months, with a roughly 24 percent relative change - one of the more favourable trials, and it used a culture-expanded product administered with hyaluronic acid rather than a same-day clinic preparation.

   Gupta PK, et al. — Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study. Am J Sports Med, 2023. DOI: 10.1177/03635465231180323.

4. A 2023 appraisal of 15 randomized and 11 non-randomized trials of culture-expanded MSCs for knee osteoarthritis found function improved relative to control in 11 of 15 RCTs and cartilage protection or repair reported in 18 of 21 imaging studies, but noted the total sample of 610 patients limits any definitive conclusion.

   Copp G, et al. — Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol, 2023. DOI: 10.1038/s41423-023-01020-1.

5. A systematic review of 13 phase I/II randomized trials of MSC injections found 10 of 11 studies reporting cartilage outcomes described a benefit on cartilage volume, morphology or quality - but 16 eligible trials remained unpublished, which is exactly the pattern that inflates an apparent effect.

   Gong J, et al. — Effect of Stem Cell Injections on Osteoarthritis-related Structural Outcomes: A Systematic Review. J Rheumatol, 2021. DOI: 10.3899/jrheum.200021.

6. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.